14
Phase 2–4 trials
Neuroscience · Live ClinicalTrials.gov data
Donanemab (Kisunla) clinical trial pipeline
ClinicalTrials.gov lists 14 phase 2–4 trials for donanemab, 4 of them actively recruiting. The next phase 3 primary completion among them is expected Nov 2027. Refreshed daily — add up to four competitors to compare pipelines side by side.
7
Phase 3 trials
4
Actively recruiting
Nov 2027
Next phase 3 primary completion
10,612
Participants across trials
Eli Lilly and Company
Lead sponsor by trial count
donanemab (14)11 active2017–2032
donanemab
'17
'19
'21
'23
'25
'27
'29
'31
donanemab
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)P2
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)P3
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)P2
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)P3
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)P3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)P3
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)P3
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's DiseaseP2
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseP3
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)P2
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).P3
ATPP2
ALADDINP4
ATPP2
Upcoming readouts
9 ahead · donanemab
Select a trial to load its full ClinicalTrials.gov record.
Key donanemab trials
Top 12 of the 14 registered phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06911944 | ALADDIN — Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation | Phase 4 | Not yet recruiting | Dec 2028 |
| NCT07602582 | A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | Phase 3 | Recruiting | Sept 2029 |
| NCT07571161 | Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Dise… | Phase 3 | Recruiting | Apr 2030 |
| NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | Phase 3 | Active, not recruiting | Apr 2023 |
| NCT05738486 | A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZ… | Phase 3 | Active, not recruiting | May 2024 |
| NCT05026866 | A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | Phase 3 | Active, not recruiting | Nov 2027 |
| NCT05508789 | A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5… | Phase 3 | Active, not recruiting | May 2028 |
| NCT05108922 | A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's D… | Phase 3 | Completed | Sept 2022 |
| NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | Phase 2 | Recruiting | Aug 2028 |
| NCT06957418 | ATP — Alzheimer's Tau Platform: Master Protocol | Phase 2 | Recruiting | Aug 2028 |
| NCT07167966 | ATP — Alzheimer's Tau Platform: Regimen A - AADvac1 | Phase 2 | Enrolling by invitation | Aug 2028 |
| NCT06996730 | A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutatio… | Phase 2 | Not yet recruiting | Jun 2030 |
Related drug pipelines
FAQ
- How many clinical trials are running for donanemab?
- ClinicalTrials.gov currently lists 14 phase 2–4 donanemab trials: 6 phase 2, 7 phase 3, and 1 phase 4. 4 are actively recruiting.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare donanemab against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.